Equity Research firms currently have a positive stance on shares of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE). The majority of analysts covering the equity have a consensus Strong Buy recommendation on the stock, yielding a score of 1.40. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $28.67 on a short term basis.
At the time of writing, the stock was trading at $14.07. This represents a change from the opening price of 0.53%. In terms of performance, year to date, the stock is 31.28%. The monthly stock performance comes in at 28.85%. For the quarter, shares are performing at 79.62%. Weekly performance analysis shows the equity at 2.88%.
In taking a look at technical levels, shares are trading 32.79% away from the 50 day simple moving average and 59.54% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -34.73% away from it’s 52- week high and 203.33% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Zynerba Pharmaceuticals, Inc.’s RSI stands at 65.69. In looking at volatility levels, the shares saw weekly volatility of 7.29% and 8.70% over the past month.